A new study on the effect of the anti-obesity drug rimonabant on liver function in obese rats found that it reduced markers of liver damage, decreased levels of pro-inflammatory proteins, and improved lipid profiles.
An overexpressed gene found at the scene of a variety of tumors is implicated in the development of two types of malignant brain cancer in a paper by researchers at The University of Texas M. D. Anderson Cancer Center to be published in the Proceedings of the National Academy of Sciences.
In what they call a “stunning research advance,” investigators at Georgetown University Medical Center have been able to use simple, nontoxic chemical injections to add and remove fat in targeted areas on the bodies of laboratory animals. They say the discovery, published online in Nature Medicine on July 1, could revolutionize human cosmetic and reconstructive plastic surgery and treatment of diseases associated with human obesity.
Inhaled insulin, taken before meals, can improve blood glucose control for people with type 2 diabetes who have not had good results with short-acting injected insulin that is taken in addition to the baseline insulin administered throughout the day and night, according to a new review of the body of published research.
Umbilical cord blood may safely preserve insulin production in children newly diagnosed with type 1 diabetes, according to findings from a small national pilot study presented at the American Diabetes Association?s 67th Scientific Sessions in Chicago.
A family-based weight management program developed by researchers at Yale School of Medicine was more effective at reducing weight, body fat, body mass index (BMI) and insulin sensitivity than traditional clinic-based weight counseling.
A new study published on bmj.com questions the value of blood glucose monitoring among patients with well-controlled, non-insulin dependent (type 2) diabetes.
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) announced study results comparing treatment with BYETTA(R) (exenatide) injection with insulin glargine in people with type 2 diabetes.
Novo Nordisk (NYSE:NVO) has announced results of a new study that further demonstrated the safety and efficacy of insulin Levemir? (insulin detemir [rDNA origin] injection).
Galvus (vildagliptin) by Novartis AG (NYSE: NVS), a new once-daily oral treatment for type 2 diabetes submitted for approval in the US and Europe, has been shown in new clinical data to deliver consistent and robust blood sugar reductions in patients with this progressive disease estimated to affect about 246 million people worldwide.